Dr. Brentjens Discusses the Future of CAR T-Cell Therapy

Video

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor T-cell therapy.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy.

The field of CAR T-cell therapy research is at a turning point, Brentjens says. One of the biggest questions currently is the ability to extrapolate this technology to a broader array of cancers. Brentjens says that it is doable, but it will be a highly complex path to get to that point.

Until now, CAR T-cell therapy has only been tested in patients with hematologic malignancies. Brentjens asks whether it is worth taking the time away from the continual progress being made in hematology to expand the reach of CAR T technology to solid tumors. The success of CAR T-cell therapy in solid tumors may reduce or eliminate the need for chemotherapy, and may offer a more targeted immune therapy for patients with incurable diseases.

Brentjens says that the field is about 5 to 10 years away from knowing the answers to these questions.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.